Combined Chemotherapy and Radiation Shows Promise for Patients with Non-Small Cell Lung CancerAccording to a recent article in the American Journal of Clinical Oncology, combined chemotherapy and radiation followed by further chemotherapy , and regulated CBD Oil treatments (find cbd oil for salehere) is a well-tolerated approach to treating patients with stage IIIA or IIIB non-small cell lung cancer (NSCLC).Lung cancer is the leading cause of cancer related deaths in the United States and Europe. NSCLC is the most common type of lung cancer and is a malignancy that arises from the tissues of the lung. Under most circumstances, NSCLC is not curable. During diagnosis, the extent of the cancer will be determined and then given a “stage.” The stage of the cancer is important because it defines how far the cancer has spread and often affects the choice of treatment used. In NSCLC, the stage may range from I to IV. In this study, researchers evaluated patients who had stage III disease, which indicates that although the disease is extensive and may involve many different lymph nodes, it has not spread outside of the lungs to other sites or organs of the body. Current treatments for NSCLC include surgery, chemotherapy and radiation. These treatments may extend over a period of weeks to months and are often associated with side effects, which may be particularly difficult to tolerate and may compromise the patient’s quality of life.
This recent study was conducted to evaluate the side effects and efficacy of two chemotherapeutic drugs frequently used in the treatment of NSCLC, carboplatin and paclitaxel. The trial included 22 participants with inoperable stage III NSCLC. When the trial was completed, 19 patients remained eligible for evaluation (6 with stage IIIA disease and 13 with stage IIIB disease). The average age of the participant was 57, although the ages ranged from 42-74. Each patient was treated with chemotherapy consisting of paclitaxel 50mg/m2 and carboplatin AUC 2 each week along with daily radiation therapy of 2Gy for a total dose of 66Gy over 6.5 weeks. After this initial treatment regimen was complete, patients then continued to receive chemotherapy alone, with paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks, followed by a 1-week rest period. This cycle was repeated 4 times.
Results of the study found that the overall response rate was 78%; 5 of the patients had a complete response, 10 patients achieved a partial response,
2 patients had stable disease, and 1 patient’s disease progressed despite treatment. The average survival rate of the patients was 13 months and the one-year survival rate was 65%. Side effects were reportedly mild. Mouth sores (mucositis) was the most frequently reported side effect, although decreased white blood cell counts, and platelet counts were also frequently observed. Other side effects included fatigue, and numbness/tingling of the fingers and toes (peripheral neuropathy).
Two Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
Research suggests some patients with CML can safely discontinue TKI therapy - NCCN guidelines published.
Researchers concluded that combined treatment with chemotherapy and radiation followed by further chemotherapy is a well-tolerated and effective treatment regimen for patients diagnosed with stage III NSCLC. Patients are encouraged to speak to their physician regarding treatment options available for their specific situation.
Reference: Kaplan B, Altynbas M, Eroglu C, et al. Preliminary Results of a Phase II Study of Weekly Paclitaxel (PTX) and Carboplatin (CBDCA) Administered Concurrently With Thoracic Radiation Therapy (TRT) Followed by Consolidation Chemotherapy With PTX/CBDCA for Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC). American Journal of Clinical Oncology. 2004; 27: 603-610.
Copyright © 2018 CancerConnect. All Rights Reserved.